Indeed, the thiazolidinedione class of drugs, the PPARγ full agonists, has a long history of use in treating Type 2 diabetes mellitus for its insulin sensitizing effects, though multiple side effects exist including obesity, water retention, increased risk of cardiovascular diseases and bone fractions. The gene discussed is INS; the disease is diabetes mellitus.